JPWO2019092283A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019092283A5 JPWO2019092283A5 JP2020544151A JP2020544151A JPWO2019092283A5 JP WO2019092283 A5 JPWO2019092283 A5 JP WO2019092283A5 JP 2020544151 A JP2020544151 A JP 2020544151A JP 2020544151 A JP2020544151 A JP 2020544151A JP WO2019092283 A5 JPWO2019092283 A5 JP WO2019092283A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- strand
- nucleotides
- formula
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004707 nucleic acids Proteins 0.000 claims 22
- 150000007523 nucleic acids Chemical class 0.000 claims 22
- 102000039446 nucleic acids Human genes 0.000 claims 22
- 125000003729 nucleotide group Chemical group 0.000 claims 13
- 239000002773 nucleotide Substances 0.000 claims 12
- 239000003446 ligand Substances 0.000 claims 7
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 5
- 230000004048 modification Effects 0.000 claims 4
- 238000012986 modification Methods 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000005647 linker group Chemical group 0.000 claims 3
- 102100040214 Apolipoprotein(a) Human genes 0.000 claims 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 2
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 2
- 101710115418 Apolipoprotein(a) Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- -1 alkylene ether Chemical compound 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 206010002906 aortic stenosis Diseases 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 101150091521 lpa gene Proteins 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17201449.0 | 2017-11-13 | ||
| EP17201449.0A EP3483270A1 (en) | 2017-11-13 | 2017-11-13 | Products and compositions |
| EP18179175.7 | 2018-06-21 | ||
| EP18179175.7A EP3483271A3 (en) | 2017-11-13 | 2018-06-21 | Products and compositions |
| GB1815915.2 | 2018-09-28 | ||
| GB201815915 | 2018-09-28 | ||
| PCT/EP2018/081106 WO2019092283A1 (en) | 2017-11-13 | 2018-11-13 | Nucleic acids for inhibiting expression of lpa in a cell |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502120A JP2021502120A (ja) | 2021-01-28 |
| JPWO2019092283A5 true JPWO2019092283A5 (enExample) | 2022-08-25 |
| JP7245254B2 JP7245254B2 (ja) | 2023-03-23 |
Family
ID=66439085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544151A Active JP7245254B2 (ja) | 2017-11-13 | 2018-11-13 | 細胞におけるｌｐａの発現を抑制するための核酸 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11319537B2 (enExample) |
| EP (2) | EP3710586B1 (enExample) |
| JP (1) | JP7245254B2 (enExample) |
| KR (1) | KR102553382B1 (enExample) |
| CN (2) | CN119120476A (enExample) |
| AU (1) | AU2018363840B2 (enExample) |
| BR (1) | BR112020009152A2 (enExample) |
| CA (1) | CA3081905C (enExample) |
| DK (1) | DK3710586T3 (enExample) |
| ES (1) | ES2938193T3 (enExample) |
| FI (1) | FI3710586T3 (enExample) |
| HR (1) | HRP20230127T1 (enExample) |
| HU (1) | HUE061265T2 (enExample) |
| IL (1) | IL274503B2 (enExample) |
| LT (1) | LT3710586T (enExample) |
| MX (1) | MX2020004897A (enExample) |
| PL (1) | PL3710586T3 (enExample) |
| RS (1) | RS63955B1 (enExample) |
| SG (1) | SG11202003230UA (enExample) |
| SI (1) | SI3710586T1 (enExample) |
| WO (1) | WO2019092283A1 (enExample) |
| ZA (1) | ZA202003371B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10987735B2 (en) | 2015-12-16 | 2021-04-27 | 6K Inc. | Spheroidal titanium metallic powders with custom microstructures |
| CN108883407A (zh) | 2015-12-16 | 2018-11-23 | 阿马斯坦技术有限责任公司 | 球状脱氢金属和金属合金颗粒 |
| RS63836B1 (sr) * | 2017-04-05 | 2023-01-31 | Silence Therapeutics Gmbh | Proizvodi i sastavi |
| IL274503B2 (en) | 2017-11-13 | 2024-10-01 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of lpa in a cell |
| JP2021511042A (ja) | 2018-01-16 | 2021-05-06 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ａｌｄｈ２発現を阻害するための組成物及び方法 |
| WO2019246257A1 (en) | 2018-06-19 | 2019-12-26 | Amastan Technologies Inc. | Process for producing spheroidized powder from feedstock materials |
| JP7245328B2 (ja) * | 2018-11-13 | 2023-03-23 | サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 細胞におけるｌｐａの発現を抑制するための核酸 |
| CA3135402A1 (en) * | 2019-04-04 | 2020-10-08 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression in the central nervous system |
| KR20220002998A (ko) | 2019-04-30 | 2022-01-07 | 6케이 인크. | 기계적으로 합금된 분말 공급원료 |
| EP4414470A3 (en) | 2019-11-18 | 2024-10-23 | 6K Inc. | Unique feedstocks for spherical powders and methods of manufacturing |
| US20230078200A1 (en) * | 2019-12-09 | 2023-03-16 | Amgen Inc. | RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION |
| KR20230029836A (ko) | 2020-06-25 | 2023-03-03 | 6케이 인크. | 마이크로복합 합금 구조 |
| JP7476422B2 (ja) | 2020-08-05 | 2024-04-30 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ｌｐａ発現を阻害するための組成物及び方法 |
| US11963287B2 (en) | 2020-09-24 | 2024-04-16 | 6K Inc. | Systems, devices, and methods for starting plasma |
| US20240035029A1 (en) | 2020-10-16 | 2024-02-01 | Sanofi | Rna compositions and methods for inhibiting lipoprotein(a) |
| US11919071B2 (en) | 2020-10-30 | 2024-03-05 | 6K Inc. | Systems and methods for synthesis of spheroidized metal powders |
| MX2023005198A (es) * | 2020-11-05 | 2023-05-16 | Amgen Inc | Metodos para tratar la enfermedad cardiovascular aterosclerotica con constructos de iarn dirigidos a lpa. |
| EP4237561A1 (en) | 2020-12-23 | 2023-09-06 | Argonaute Rna Limited | Treatment of cardiovascular disease |
| CA3197544A1 (en) | 2021-01-11 | 2022-07-14 | 6K Inc. | Methods and systems for reclamation of li-ion cathode materials using microwave plasma processing |
| KR20230164699A (ko) | 2021-03-31 | 2023-12-04 | 6케이 인크. | 질화금속 세라믹의 적층 제조를 위한 시스템 및 방법 |
| JP2024531728A (ja) | 2021-09-14 | 2024-08-29 | アルゴノート アールエヌエー リミテッド | 心血管疾患の処置 |
| MX2024005862A (es) | 2021-11-16 | 2024-07-10 | Shanghai Argo Biopharmaceutical Co Ltd | Composiciones y metodos para inhibir la expresion de la proteina angiotensinogeno (agt). |
| IL312743A (en) * | 2021-11-18 | 2024-07-01 | Novartis Ag | Compounds targeting PMP22 for the treatment of Charcot-Marie-Shen disease |
| CA3240273A1 (en) * | 2021-11-24 | 2023-06-01 | Adarx Pharmaceuticals, Inc. | Complement factor b-modulating compositions and methods of use thereof |
| TW202345865A (zh) * | 2022-01-24 | 2023-12-01 | 大陸商上海舶望製藥有限公司 | 抑制LPA(Apo(a))蛋白表達的組合物和方法 |
| CN114703184B (zh) * | 2022-03-11 | 2024-06-18 | 厦门甘宝利生物医药有限公司 | Lpa抑制剂及其用途 |
| WO2023220744A2 (en) | 2022-05-13 | 2023-11-16 | Alnylam Pharmaceuticals, Inc. | Single-stranded loop oligonucleotides |
| US12261023B2 (en) | 2022-05-23 | 2025-03-25 | 6K Inc. | Microwave plasma apparatus and methods for processing materials using an interior liner |
| US12040162B2 (en) | 2022-06-09 | 2024-07-16 | 6K Inc. | Plasma apparatus and methods for processing feed material utilizing an upstream swirl module and composite gas flows |
| EP4547683A2 (en) | 2022-06-30 | 2025-05-07 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
| US12094688B2 (en) | 2022-08-25 | 2024-09-17 | 6K Inc. | Plasma apparatus and methods for processing feed material utilizing a powder ingress preventor (PIP) |
| CN115851723B (zh) * | 2022-10-24 | 2023-10-03 | 厦门甘宝利生物医药有限公司 | 一种抑制lpa基因表达的rna抑制剂及其应用 |
| US12195338B2 (en) | 2022-12-15 | 2025-01-14 | 6K Inc. | Systems, methods, and device for pyrolysis of methane in a microwave plasma for hydrogen and structured carbon powder production |
| JP2026502533A (ja) * | 2023-01-13 | 2026-01-23 | イーライ リリー アンド カンパニー | 治療用オリゴヌクレオチド含有医薬組成物及びそれを用いる投与レジメン |
| EP4709855A2 (en) | 2023-05-12 | 2026-03-18 | Alnylam Pharmaceuticals, Inc. | Single-stranded loop oligonucleotides |
| EP4714939A1 (en) | 2023-05-19 | 2026-03-25 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Sulfonamide compound, preparation method therefor, and pharmaceutical use thereof |
| WO2025007872A1 (zh) | 2023-07-04 | 2025-01-09 | 石药集团中奇制药技术（石家庄）有限公司 | 一种抑制LP(a)基因表达的dsRNA分子及其应用 |
| WO2025082058A1 (zh) * | 2023-10-16 | 2025-04-24 | 润佳(上海)医药技术有限公司 | 一种抑制LPA基因表达的dsRNA及其用途 |
| TW202540420A (zh) * | 2023-11-15 | 2025-10-16 | 大陸商北京加科瑞康醫藥科技有限公司 | 用於抑制LPA的基因表現的siRNA，含其的組合物及其用途 |
| CN120098993A (zh) * | 2023-12-05 | 2025-06-06 | 广东东阳光药业股份有限公司 | 一种新型的双链siRNA、其缀合物及其用途 |
| WO2026008063A1 (en) * | 2024-07-05 | 2026-01-08 | Geneditbio Limited | Methods and compositions for lpa gene editing and therapy using crispr system |
| WO2026046152A1 (zh) * | 2024-08-26 | 2026-03-05 | 倍臻生物技术（苏州）有限公司 | 修饰的双链核糖核酸及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US7259150B2 (en) * | 2001-08-07 | 2007-08-21 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein (a) expression |
| US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
| US20060160759A1 (en) * | 2002-09-28 | 2006-07-20 | Jianzhu Chen | Influenza therapeutic |
| US20110110886A1 (en) * | 2008-06-13 | 2011-05-12 | Yale University | Small molecule inhibitors of autotaxin and methods of use |
| US10125362B2 (en) * | 2012-05-22 | 2018-11-13 | Olix Pharmaceuticals, Inc. | RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor |
| US20160272970A1 (en) * | 2015-03-17 | 2016-09-22 | Arrowhead Madison Inc. | RNA Interference Agents |
| JOP20210043A1 (ar) * | 2015-10-01 | 2017-06-16 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| EP3228326A1 (en) | 2016-04-05 | 2017-10-11 | Silence Therapeutics GmbH | Nucleic acid linked to a trivalent glycoconjugate |
| RS63836B1 (sr) | 2017-04-05 | 2023-01-31 | Silence Therapeutics Gmbh | Proizvodi i sastavi |
| EP3735461A1 (en) | 2017-11-13 | 2020-11-11 | Silence Therapeutics GmbH | Nucleic acids for inhibiting expression of aldh2 in a cell |
| IL274503B2 (en) | 2017-11-13 | 2024-10-01 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of lpa in a cell |
| JP7245328B2 (ja) | 2018-11-13 | 2023-03-23 | サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 細胞におけるｌｐａの発現を抑制するための核酸 |
-
2018
- 2018-11-13 IL IL274503A patent/IL274503B2/en unknown
- 2018-11-13 CN CN202411317688.6A patent/CN119120476A/zh active Pending
- 2018-11-13 DK DK18803644.6T patent/DK3710586T3/da active
- 2018-11-13 KR KR1020207016884A patent/KR102553382B1/ko active Active
- 2018-11-13 HR HRP20230127TT patent/HRP20230127T1/hr unknown
- 2018-11-13 MX MX2020004897A patent/MX2020004897A/es unknown
- 2018-11-13 ES ES18803644T patent/ES2938193T3/es active Active
- 2018-11-13 EP EP18803644.6A patent/EP3710586B1/en active Active
- 2018-11-13 AU AU2018363840A patent/AU2018363840B2/en active Active
- 2018-11-13 JP JP2020544151A patent/JP7245254B2/ja active Active
- 2018-11-13 RS RS20230097A patent/RS63955B1/sr unknown
- 2018-11-13 SG SG11202003230UA patent/SG11202003230UA/en unknown
- 2018-11-13 CN CN201880073189.3A patent/CN111465694A/zh active Pending
- 2018-11-13 PL PL18803644.6T patent/PL3710586T3/pl unknown
- 2018-11-13 EP EP22208120.0A patent/EP4219716A3/en active Pending
- 2018-11-13 WO PCT/EP2018/081106 patent/WO2019092283A1/en not_active Ceased
- 2018-11-13 FI FIEP18803644.6T patent/FI3710586T3/fi active
- 2018-11-13 SI SI201830845T patent/SI3710586T1/sl unknown
- 2018-11-13 HU HUE18803644A patent/HUE061265T2/hu unknown
- 2018-11-13 LT LTEPPCT/EP2018/081106T patent/LT3710586T/lt unknown
- 2018-11-13 CA CA3081905A patent/CA3081905C/en active Active
- 2018-11-13 BR BR112020009152-9A patent/BR112020009152A2/pt not_active Application Discontinuation
- 2018-11-13 US US16/763,458 patent/US11319537B2/en active Active
-
2020
- 2020-06-05 ZA ZA2020/03371A patent/ZA202003371B/en unknown
-
2022
- 2022-03-17 US US17/697,405 patent/US12054717B2/en active Active
-
2024
- 2024-06-17 US US18/745,632 patent/US20240327843A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019092283A5 (enExample) | ||
| IL274503B2 (en) | Nucleic acids for inhibiting expression of lpa in a cell | |
| JP4012579B2 (ja) | ２’−エーテル基を有するヌクレオシド及びオリゴヌクレオチド | |
| US20210017214A1 (en) | Galnac phosphoramidites, nucleic acid conjugates thereof and their use | |
| JP2023100832A5 (enExample) | ||
| JP2024028453A5 (enExample) | ||
| CN116333013B (zh) | 一种靶向配体 | |
| CN110832077B (zh) | 用于抑制α-ENaC表达的RNAi剂及使用方法 | |
| KR20180134364A (ko) | 트리틸-모노-GalNAc 화합물 및 이의 용도 | |
| CN113795582A (zh) | 核酸、药物组合物与缀合物及制备方法和用途 | |
| JPWO2021030778A5 (enExample) | ||
| CA2453301A1 (en) | Synthetic double-stranded oligonucleotides for specific inhibition of gene expression | |
| FI3880818T3 (fi) | Nukleiinihappoja LPA:n ekspression inhiboimiseksi solussa | |
| JPWO2019105414A5 (enExample) | ||
| JPWO2020099476A5 (enExample) | ||
| JPWO2020247818A5 (enExample) | ||
| JPWO2019105435A5 (enExample) | ||
| JP2017514479A5 (enExample) | ||
| AU769619B2 (en) | Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids | |
| JPWO2022028462A5 (enExample) | ||
| JPWO2020038377A5 (enExample) | ||
| JPWO2020063198A5 (enExample) | ||
| EP0790837A1 (en) | Oligonucleotide-dendrimer conjugates | |
| JP2006067889A (ja) | Ｐｅｏと二本鎖核酸のコンジュゲート | |
| US6017895A (en) | Oligonucleotides possessing zwitterionic moieties |